In November it was found out that the Government had agreed with the respective company to buy 2 million doses of medicine, the amount was not detailed
The National Medicines Directorate (DNM) today authorized the import, distribution and use of the Covid-19 vaccine from AstraZeneca, based in Cambridge, United Kingdom.
According to the statement published by DNM, it is a “special emergency authorization” and was granted today in a special session.
You may be interested in: The government must report on the risks and benefits of vaccines against COVID-19
In addition, the regulatory institution justifies that the authorization granted to the medicinal product is technically and legally based on evidence generated by the manufacturer and the health authorities of other countries that have previously issued emergency authorizations for that product.
The latest official figures represent 45,960 confirmed cases of patients with Covid-19; 1,327 deaths are also mentioned.
In late November, it was learned that the government had agreed to buy 2 million doses of the covid-19 vaccine developed by AstraZeneca and Oxford University.
You may be interested in: Medical College: The government has an agreement with Pfizer to apply this vaccine in El Salvador
At this time, the Government has not made public the amounts involved in purchasing any of these vaccines and has only announced that their application in the country will not have an additional cost to the population and also each person can decide whether to accept or not. injection.
Doubts of specialists
AstraZeneca has yet to conduct further studies to verify the operation and effectiveness of its vaccine against COVID-19, so it seems “impossible to have it in El Salvador in the first quarter of the year,” said infectologist Iván Solano Leiva in a statement interview for Channel 33.
You may be interested in: Infectious diseases are asking for more support from UES to investigate the new variant of COVID-19
The application of AstraZeneca in the first quarter of 2021 was an announcement made by the President of the Republic, Nayib Bukele, in November last year, although the President explained that the agreement made the company perform clinical tests on thousands of patients.
Specialist Solano Leiva confirmed that, as a member of the Advisory Committee on Immunization Practices (CAPI) working with the Ministry of Health, he is aware that last Wednesday the Salvadoran government was given technical approval to apply the Pfizer BionTech vaccine in the country. Dr. Milton Brizuela, president of the Medical College, had told El Diario de Hoy.
The delay in AstraZeneca has led the Government to negotiate with BionTech Pfizer, said Solano Leiva, adding that “we are more likely to have it in the first quarter of 2021”, as expected by the Executive, but with the British drug- Swedish with whom he had already negotiated.
